Related Experiment Video
Updated: Nov 13, 2025
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.8K
Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold
Carol Mansfield1, Kelley Myers1, Kathleen Klein1
1RTI Health Solutions, Research Triangle Park, NC 27709, USA.
Future Oncology (London, England)
|March 12, 2021
Summary
Melanoma patients tolerate higher pyrexia risk when treatment benefits are known. Understanding efficacy significantly impacts acceptable adverse event levels in cancer therapy decisions.
Area of Science:
- Oncology
- Clinical Decision Making
- Patient-Reported Outcomes
Background:
- Adverse events like pyrexia can influence cancer treatment adherence and patterns.
- Understanding patient risk tolerance for side effects is crucial for treatment selection.
Purpose of the Study:
- To evaluate pyrexia risk tolerance in melanoma patients with unknown versus known treatment efficacy.
- To compare risk acceptance between different stages of melanoma.
Main Methods:
- US patients with Stage III or Stage IV melanoma were presented with hypothetical treatment options.
- Participants chose between treatments based on survival benefits and pyrexia risk, first with unknown and then with known efficacy.
- Maximum acceptable pyrexia risk was systematically determined.
Main Results:
- Stage III melanoma patients showed significantly higher pyrexia risk tolerance when efficacy was known (85%) versus unknown (34%).
- Stage III unresectable/Stage IV melanoma patients also accepted higher pyrexia risk with known efficacy (66%) compared to unknown (57%).
Conclusions:
- Melanoma patient acceptance of pyrexia risk increases substantially when treatment benefits are clearly understood.
- Knowledge of treatment efficacy is a key factor in patient willingness to accept potential adverse events.
